BiotechTube

JBT-101 + Placebo

Phase 2Completed
0 watching 0 views this week⚡ Active
44
Hype Score

Development Stage

✓
Pre-clinical
✓
Phase 1
3
Phase 2
4
Phase 3
5
Approved
Indication / Disease

Systemic Lupus Erythematosus

Conditions

Systemic Lupus Erythematosus, SLE, Lupus

Trial Timeline

Dec 21, 2017 → Jul 28, 2021

NCT ID
NCT03093402

About JBT-101 + Placebo

JBT-101 + Placebo is a phase 2 stage product being developed by Corbus Pharmaceuticals for Systemic Lupus Erythematosus. The current trial status is completed. This product is registered under clinical trial identifier NCT03093402. Target conditions include Systemic Lupus Erythematosus, SLE, Lupus.

Hype Score Breakdown

Clinical
17
Activity
12
Company
2
Novelty
5
Community
5

Clinical Trials (2)

NCT IDPhaseStatus
NCT03093402Phase 2Completed
NCT02466243Phase 2Terminated

Competing Products

20 competing products in Systemic Lupus Erythematosus

See all competitors
ProductCompanyStageHype Score
Tabalumab Auto-Injector + Tabalumab Prefilled SyringeEli LillyPhase 3
77
Baricitinib + PlaceboEli LillyPhase 2
52
MRA(Tocilizumab) + placeboChugai PharmaceuticalPhase 3
77
MRA(Tocilizumab)Chugai PharmaceuticalPhase 3
77
MRA(Tocilizumab)Chugai PharmaceuticalPhase 3
77
DS-7011a + PlaceboDaiichi SankyoPhase 1
33
DS-7011a + PlaceboDaiichi SankyoPhase 1/2
41
Bocidelpar + PlaceboAstellas PharmaPhase 1
33
Parenteral micafungin application + Other parenteral antifungal drugsAstellas PharmaPre-clinical
23
MicafunginAstellas PharmaPhase 2
52
E6742EisaiPhase 1/2
41
KHK4827Kyowa KirinPhase 1
33
KHK4827 + PlaceboKyowa KirinPhase 3
77
Baricitinib + PlaceboEli LillyPhase 3
77
Baricitinib + CyclophosphamideEli LillyApproved
85
Baricitinib + PlaceboEli LillyPhase 3
77
LY2127399 + Placebo every 2 weeks + Placebo every 4 weeks + Standard of CareEli LillyPhase 3
77
LY3361237 + PlaceboEli LillyPhase 2
52
LY2127399 + PlaceboEli LillyPhase 3
77
LY3361237 + PlaceboEli LillyPhase 1
33

Other Products from Corbus Pharmaceuticals

Lenabasum 5 mg + Lenabasum 20 mgPhase 3
69
Lenabasum 20 mg + Lenabasum 5 mg + PlaceboPhase 3
69
Lenabasum 20 mg + Lenabasum 5 mgPhase 2
44
JBT-101 (lenabasum)Phase 2
44
JBT-101 + Placebo + Part B Open-Label ExtensionPhase 2
44